This website will close on 30 April 2024. After this date, your content will not be accessible. Please contact info@healthinnovationnwc.nhs.uk for more information.

Behavidence

Roy Cohen

The most accurate digital phenotyping platform for mental health

Behavidence develops machine learning based tools to detect and assist with remote monitoring and management of mental health conditions through passive digital biomarkers. The company was founded by a neuroscientist, neuropsychologist, physician and bioengineer with the passion to improve the lives of millions suffering from psychiatric and neurological disorders. Founded in 2020, Behavidence now offers multiple digital phenotyping models that can predict disorders such as depression, anxiety, ADHD and more. These digital phenotyping solutions have been adopted by health organizations, tech, commercial and government entities. The Behavidence products can be used as a measurement based outcome to monitor employee burnout, stress, predict relapse of conditions, screening and remote monitoring for clinical interventions and comorbid conditions. This disruptive solution offers absolute user privacy, zero respondent burden and real time feedback.

Innovations